Statins and myocardial hypertrophy

Coronary Artery Disease

Volumn 15, Issue 5, 2004, Pages 247-250

  Nakagami, Hironori ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

3 hydroxyl 3 methylglutaryl coenzyme A reductase inhibitors; Antioxidants; Cardiac hypertrophy; Small GTP binding proteins; Statins

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

CONGESTIVE CARDIOMYOPATHY; ENZYME ACTIVATION; HEART DILATATION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; ISOPRENYLATION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CARDIOMEGALY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MONOMERIC GTP-BINDING PROTEINS; MYOCYTES, CARDIAC; NADPH OXIDASE; OXIDATIVE STRESS; RAC1 GTP-BINDING PROTEIN;

EID: 4043058007     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000130229.18685.b9     Document Type: Review

References (32)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307. This large randomized study demonstrates that the relative risk reduction conferred by statin treatment in individuals with high cholesterol levels.
2. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996; 347:102-103.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009. This large randomized study demonstrates that the relative risk reduction conferred by statin treatment in individuals with average cholesterol levels.
4. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272:31725-31729.
5. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103:993-999.
6. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-1965.
7. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995; 77:258-265.
8. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 1996; 271:3221-3228.
9. Tapon N, Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 1997; 9:86-92.
10. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein Rac regulates growth factor-induced membrane ruffling. Cell 1992; 70:401-410.
11. Wang SM, Tsai YJ, Jiang MJ, Tseng YZ. Studies on the function of RhoA protein in cardiac myofibrillogenesis. J Cell Biochem 1997; 66:43-53.
12. Thorburn J, Xu S, Thorburn A. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. Embo J 1997; 16:1888-1900.
13. Fuller SJ, Gillespie-Brown J, Sugden PH. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem 1998; 273:18146-18152.
14. Hunter JJ, Tanaka N, Rockman HA, Ross J, Jr., Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995; 270:23173-23178.
15. Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW, Ross J, Jr., et al. Cardiac-specific over-expression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest 1999; 103:1627-1634.
16. Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem 1996; 271:31185-31190.
17. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, Price RL, et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 2000; 105:875-886.
18. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11:2295-2322.
19. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279:509-514.
20. Laufs U, La Fata V, Plutzky J, Liao JK. Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-1135.
21. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273:24266-24271. This study demonstrates an important principle of cholesterol-independent effects of statin treatment in human endothelial cells showing that inhibition of isoprenylation of the small G protein RhoA by statin treatment leads to increased eNOS mRNA stability.
22. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108:1429-1437. This is the first study to show that statins can prevent the development of cardiac hypertrophy through a non-lipid, antioxidant mechanism.
23. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor. Circulation 2001; 104:576-581.
24. Bell JP, Mosfer SI, Lang D, Donaldson F, Lewis MJ. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol Heart Circ Physiol 2001; 281:H1704-H1710.
25. Date MO, Morita T, Yamashita N, Nishida K, Yamaguchi O, Higuchi Y, et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in an in vivo murine pressure-overload model. J Am Coll Cardiol 2002; 39:907-912.
26. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
27. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32:488-495.
28. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999; 274:19814-19822.
29. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998; 329:653-657.
30. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-κ and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 1997; 96:2361-2367.
31. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002; 105:293-296.
32. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2alpha formation. J Cardiovasc Pharmacol 2002; 40:868-874.